AngioLab (XKRX:251280) Scaled Net Operating Assets : -0.15 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AngioLab Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

AngioLab's operating assets for the quarter that ended in Dec. 2023 was ₩1,114.3 Mil. AngioLab's operating liabilities for the quarter that ended in Dec. 2023 was ₩1,845.2 Mil. AngioLab's Total Assets for the quarter that ended in Dec. 2022 was ₩4,997.0 Mil. Therefore, AngioLab's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was -0.15.

AngioLab Scaled Net Operating Assets Historical Data

The historical data trend for AngioLab's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Scaled Net Operating Assets Chart

AngioLab Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-2.09

0.08

0.18

0.09

-0.15

AngioLab Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Scaled Net Operating Assets	Get a 7-Day Free Trial			-2.09	0.08	0.18	0.09	-0.15

Competitive Comparison of AngioLab's Scaled Net Operating Assets

For the Biotechnology subindustry, AngioLab's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AngioLab's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AngioLab's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where AngioLab's Scaled Net Operating Assets falls into.

AngioLab Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

AngioLab's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(1114.317	-	1845.203)	/	4997.03
=	-0.15

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	3918.531	-	2804.214
=	1114.317

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	1949.978	-	43.969	-	60.806
=	1845.203

AngioLab's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Dec. 2022 )
=	(1114.317	-	1845.203)	/	4997.03
=	-0.15

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	3918.531	-	2804.214
=	1114.317

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	1949.978	-	43.969	-	60.806
=	1845.203

AngioLab Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of AngioLab's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioLab (XKRX:251280) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN

Website

http://www.angiolab.co.kr

AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines